All Categories
ENEN
Epidermal Growth factor (EGF)

Epidermal Growth factor (EGF) Deutschland

Home >  Modality  >  Aesthetic Medicines  >  Epidermal Growth factor (EGF)

Modality

Epidermal Growth Factor (EGF)

Epidermal growth factor (EGF) is a 53-amino-acid cytokine proteolytically cleaved from a large integral membrane protein precursor. And it was the first growth factor to be discovered.

Recombinant epidermal growth factors have been extensively studied and developed as cancer vaccines (CimaVax EGF, regEFP-p64K/Mont) and as skin injury/wound healing therapeutics (e.g., Heberprot-P, Regen-D 150, Easyef).

Application of EGF
Recombinant EGF for Wound Healing/Skin Lesions

The mechanism of action of epidermal growth factors is connected with increased proliferation of keratinocytes and higher tensile strength of newborn skin. Current EGF-based therapies include topical, cutaneous, and intralesional injections.

Recombinant human epidermal growth factor has been used in the treatment of diabetic foot ulcers (Heberprot-P, Regen-D 150, Easyef), vascular ulcers and bed sores (Regen-D 150), burns and site donor skin grafts (Regen-D 60).

EGF as Cancer Therapeutical Vaccines (CimaVax EGF)

The EGF-PTI vaccine based on the epidermal growth factor has been approved in Cuba for use in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) after front-line CTP. As the first-in-class therapeutic vaccine for lung cancer, CimaVax-EGF consists of recombinant human EGF manufactured in yeast, and it is chemically linked to the recombinant P64K protein derived from Neisseria meningitides and produced in Escherichia coli. The EGF-PTI vaccine is adjuvanted with an aluminium hydroxide or Contained ISA51. It is developed by CIMAB. Bioven has been granted exclusive rights to CimaVax-EGF in the United States and Biotech Pharmaceuticals in China.

Yaohai Bio-Pharma Offers One-Stop CDMO Solution for EGF
Epidermal growth factor (EGF) Pipelines

Generic Name

Brand Name/ Alternative Name

Expression System

Indications

Manufacturer

R&D Stage

Nepidamine

Beta-urogastrone, Easyef, Urogastrone, DWP-401

Escherichia coli (E. coli)

Diabetic Foot Ulcer, Oral Mucositis,Dry Eye Syndrome

Daewoong Pharmaceutical Co., Ltd.

Approved

Topical recombinant human epidermal growth factor

Kanghesu(康合素)

E. coli

ulcers, burns, wounds

Haohai Biological Technology Co., Ltd.

Approved

Recombinant human epidermal growth factor derivative eye drops

GeneSoft, rEGF derivative, Kim In-soo

E. coli

Dry eye disease, corneal disease, burns

Shenzhen Watsin Genetech Co., Ltd., Uni-Bio Science Group

Approved

Recombinant human epidermal growth factor topical solution

GeneTime, rEGF, Kim In-tai

E. coli

Dry eye disease, corneal disease, burns

Shenzhen Watsin Genetech Co., Ltd., Uni-Bio Science Group

Approved

PX-070101

Pending update

Pending update

diabetic foo

Praxis Pharmaceutical

Approved

Recombinant epidermal growth factor

Heberprot-P, hrecEGF, Heberprot-P 75

Pending update

burns, diabetic foot

Elea Spa

Approved

Epidermal growth factor

Pending update

Pending update

bioMérieux SA

Approved

Recombinant epidermal growth factor

hrecEGF, REGEN-D 150, REGEN-D 60, REGEN-D 10

Pending update

burns, diabetic foot

Bharat Biotech International Limited

Approved

Recombinant human epidermal growth factor

yifu(易孚)

Yeast

burns, skin ulcers

Guilin Warnover Gene Pharmaceutical Co., Ltd.

Approved

Recombinant human epidermal growth factor eye drops

yibei(易贝)

Yeast

corneal disease, dry eye

Guilin Warnover Gene Pharmaceutical Co., Ltd.

Approved

Lyophilized mouse epidermal growth factor

yifu(一夫)

Pending update

Trauma and Injury

Hangzhou Tianmu Beidou Bio Pharmaceutical Co. Ltd.

Approved

Human epidermal growth factor (EGF) conjugate vaccine

CIMAv, CimaVax EGF, EGF vaccine (rEGF-p64K/Mont vaccine), chemical conjugate vaccine

E. coli and Yeast

Non-small cell lung cancer

Constellations Pharmaceuticals, BIOTECH PHARMACEUTICAL CO., LTD

Approved

IN-03,recombinant protein

tumor therapeutic vaccines

Pending update

tumors

In3Bio

Phase II

IN-04

Pending update

Pending update

tumors

In3Bio

Phase I

TTI-1612

oral recombinant protein

Pending update

Interstitial Cystitis/Bladder Pain Syndrome

Trillium(Acquired by Pfizer)

Phase I

MP-0274 fusion protein

CME-114, CME-119, CME-118, CME-115, DARPin-41, SPA-28, MP 0274

Pending update

tumors, solid tumors

Molecular Partners AG

Phase I

ZZ-06

recombinant Ganoderma lucidum immunomodulatory protein 70Lys

Pending update

EGFR-positive advanced solid tumors

Changchun Intellicrown Pharmaceutical Co., Ltd

Phase I
Reference:

[1] Decoster L, Wauters I, Vansteenkiste JF. Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development. Ann Oncol. 2012 Jun;23(6):1387-93. doi: 10.1093/annonc/mdr564.

Get a Free Quote

Get in touch